加拿大不列颠哥伦比亚省婴儿与母亲呼吸道合胞病毒免疫策略的成本效果
研究用离散事件模拟模型,模拟10万名新生儿至24月龄,从医疗系统视角评估五种呼吸道合胞病毒免疫策略。序贯分析显示,对高危和中危婴儿使用尼塞韦单抗最具成本效果;母亲RSVpreF疫苗联合高危婴儿尼塞韦单抗较历史标准治疗有成本效果,但增量分析未达成本效果。
要点
- 序贯分析中,对高危和中危婴儿使用尼塞韦单抗是最具成本效果的策略。
- 母亲RSVpreF疫苗联合高危婴儿尼塞韦单抗较历史标准治疗有成本效果,ICER约18,000美元/QALY。
- 母亲RSVpreF疫苗联合高危和中危婴儿尼塞韦单抗较策略2的增量ICER约119,000美元/QALY,未达成本效果。
核心结论
- 研究结果支持将尼塞韦单抗用于高危和中危婴儿作为最具成本效果的策略优先考虑。
- 母亲RSVpreF疫苗接种提供额外健康获益,且与历史标准治疗相比具有成本效果,但增量分析时未达成本效果。
研究设计与样本
- 采用离散事件模拟模型,使用加拿大不列颠哥伦比亚省的流行病学和成本数据及已发表的效力估计。
- 模型模拟10万名新生儿队列并随访至24个月。
- 从医疗系统视角进行序贯成本效果分析,按成本排序策略,排除被支配或扩展被支配选项,并逐步评估剩余策略。
- 同时进行成对分析,将每种策略直接与历史标准治疗比较。
主要发现
- 序贯分析中,策略2(对高危和中危儿童使用尼塞韦单抗)是最具成本效果的选项。
- 策略4(季节性母亲RSVpreF疫苗联合高危和中危儿童尼塞韦单抗)提供额外健康获益,但增量分析未达成本效果(ICER约119,000美元/QALY vs 策略2)。
- 策略5(对所有婴儿使用尼塞韦单抗)提供最大总体健康获益,但成本效果最差。
- 与历史标准治疗直接比较时,策略4具有成本效果(ICER约18,000美元/QALY)。
关键数值与推荐
- 策略2:对高危和中危儿童使用尼塞韦单抗,序贯分析中最具成本效果。
- 策略4:季节性母亲RSVpreF疫苗联合高危和中危儿童尼塞韦单抗,vs 策略2的ICER约119,000美元/QALY;vs 历史标准治疗的ICER约18,000美元/QALY。
- 策略5:对所有婴儿使用尼塞韦单抗,总体健康获益最大但成本效果最差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in young children and results in significant healthcare burden and costs. To reduce the impact of RSV in this population, the monoclonal antibody palivizumab has historically been used. Recently, new preventive options have become available, including a longer-acting monoclonal antibody (nirsevimab) and a maternal vaccine (RSVpreF). METHODS: We developed a discrete-event simulation model using epidemiological and cost data from British Columbia, Canada, and published efficacy estimates. The model simulated a cohort of 100,000 newborns and followed them up to 24 months. We conducted the analysis from a healthcare system perspective, evaluating five immunization strategies: (1) the historical palivizumab standard of care for high-risk children; (2) nirsevimab for high- and moderate-risk children; (3) in-season maternal RSVpreF vaccination combined with nirsevimab for high-risk children; (4) in-season maternal RSVpreF plus nirsevimab for high- and moderate-risk children; and (5) nirsevimab for all infants. We conducted a sequential cost-effectiveness analysis, ordering strategies by cost, excluding dominated or extendedly dominated options, and evaluating the remaining strategies stepwise. To support policy interpretation, we also performed a pairwise analysis comparing each strategy directly with the historical standard of care. RESULTS: In the sequential analysis, strategy 2 was the most cost-effective option. Strategy 4 provided additional health gains but was not cost-effective incrementally (ICER ≈ $119,000 per QALY vs strategy 2). Strategy 5 offered the greatest overall health benefits but was the least cost-effective option. When compared directly with the historical standard of care, however, strategy 4 was cost-effective (ICER ≈ $18,000 per QALY). INTERPRETATION: These findings support policy recommendations to prioritize nirsevimab for high- and moderate-risk infants as the most cost-effective strategy. Maternal RSVpreF vaccination offers added health benefits and is cost-effective compared with the historical standard of care, though not when considered incrementally.
引用
- Taleshi J, Paramo MV, Watts A, et al. Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, Canada. Vaccine. 2025. PMID: 41218303. doi:10.1016/j.vaccine.2025.127936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。